Sandoz

News

Sandoz will pay $265m to settle price fixing case in US

Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind

News

Sandoz makes its first post-spinout acquisition

Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in

News

AbbVie hit as CVS says it will cut Humira from formularies

CVS Health has said it will remove AbbVie’s big-selling immunology drug Humira from most of its national formulary lists of reimbursable products, and offer biosimilar ver

News

Sandoz separates from Novartis, valued at just over $11bn

Sandoz completed its long-heralded separation from Novartis on schedule this morning, with its shares trading at CHF 24 on the SIX Swiss Exchange.

News

Polpharma Bio gets first EU okay for Tysabri biosimilar

Polpharma Biologics has said it is the first company to get approval in the EU for a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri.

News

Novartis updates on Sandoz finances ahead of spin-off

Novartis confirmed this morning that it expects to complete the separation of its generic and biosimilar medicines unit Sandoz into an independent company on or around 4th

Sandoz will pay $265m to settle price fixing case in US

Sandoz makes its first post-spinout acquisition

AbbVie hit as CVS says it will cut Humira from formularies

Sandoz separates from Novartis, valued at just over $11bn

Polpharma Bio gets first EU okay for Tysabri biosimilar

Novartis updates on Sandoz finances ahead of spin-off

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Sandoz

Editor's Picks